title: Follicular non-Hodgkin's lymphoma.
abstract: FL is usually widely disseminated at presentation and responds to radiotherapy, single agent chemotherapy and combination therapy. The disease pursues a remitting and relapsing course with continuing sensitivity to brief periods of treatment until a terminal phase of drug resistance, transformation, or bone marrow failure is reached. Newly recognized prognostic factors indicative of tumour bulk include hepatosplenomegaly, B symptoms, anaemia and abnormal liver function. Using these factors it is possible to identify those patients at first diagnosis for whom conservative management is appropriate and those with a much less favourable prognosis for whom experimental treatments are being investigated.
authors.forename: C J
authors.initials: CJ
authors.lastname: Gallagher
authors.forename: T A
authors.initials: TA
authors.lastname: Lister
mesh_terms: D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis